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  INTRODUCTION 
 Infl  ammatory bowel disease (IBD) is a chronic, infl  ammatory 
disorder of the gastrointestinal tract. As such, standard therapies 
for IBD have focused on nonspecifi  c inhibition of infl  ammation 
with sulfasalazine, mesalazine, steroids, the thiopurines azathio-
prine (AZA) and 6-mercaptopurine (6-MP), and methotrexate 
(MTX) (  1  ). While these agents can be moderately eff  ective in 
maintaining corticosteroid-induced remission, relapse can be 
common (  2,3  ). In addition, thiopurine therapy of IBD carries an 
increased risk of lymphoproliferative disorders (  4  ). 
  On the basis of the unmet need for patients intolerant of or 
unresponsive to standard therapy, several antagonists of the 
proinfl   ammatory cytokine tumor necrosis factor (TNF) have 
been developed, including adalimumab, etanercept, infl  iximab, 
and certolizumab pegol. Although TNF antagonist therapy is 
generally well tolerated by patients with IBD, a unique spectrum 
of safety issues related to blocking TNF, including life-threaten-
ing and opportunistic infection, malignancy, and mortality, must 
be considered. While researchers have attempted to obtain con-
sensus on the relationship between TNF antagonist therapy and 
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    OBJECTIVES:       The objective of this study was to analyze the safety of long-term inﬂ  iximab treatment, with  /  without 
concomitant immunomodulators, across Crohn  ’  s disease (CD) and ulcerative colitis (UC) clinical trials. 
    METHODS:       To maximize sample size, we pooled primary safety data across 10 CD or UC trials, including ﬁ  ve 
randomized, controlled trials contributing data from patients who received intravenous inﬂ  iximab 5 or 
10    mg  /  kg (  n        =      1,713;   ±  azathioprine) or placebo (  n        =      406;   ±  azathioprine). Pooled incidences and 95  %   
conﬁ  dence intervals (CIs) were determined for mortality, infection, and malignancy. Standardized 
incidence ratios and 95  %   CIs were also determined for malignancies using the Surveillance, 
Epidemiology, and End Results database. 
    RESULTS:       We observed no increase in infections, serious infections, or malignancy with inﬂ  iximab vs. placebo 
in these patients with inﬂ  ammatory bowel disease (IBD). In patients with UC, but not CD, immuno-
modulator treatment (vs. treatment without immunomodulator) yielded a higher incidence (95  %   CI) 
of infections (120.07 (110.66, 130.08)  /  100 patient-years (pt-yrs) vs. 92.47 (84.54, 100.94)  /  100 
pt-yrs). Among placebo-treated patients with CD, but not UC, those with immunomodulator use 
demonstrated a higher incidence (95  %   CI) of malignancy vs. no immunomodulator treatment 
(1.84 (0.22, 6.66)  /  100 pt-yrs vs. 0.00 (0.00, 0.00)  /  100 pt-yrs). Mortality and infection-related 
mortality appeared unaffected by inﬂ  iximab or immunomodulator treatment. 
    CONCLUSIONS:       Inﬂ  iximab treatment of IBD did not appear to affect incidences of infection, mortality, or malignancy. 
Relative to patients with no immunomodulator use, immunomodulator-treated UC patients demons-
trated a higher incidence of infection and immunomodulator-plus-placebo-treated CD patients 
demonstrated a higher incidence of malignancy.   
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these relatively rare events, analyses have generally been limited 
by comparatively small study populations and short periods of 
patient follow-up. 
 Th   e TNF antagonist infl  iximab has been used to treat patients 
with moderately-to-severely active IBD for more than a decade. 
As infl  iximab was approved for the treatment of moderate-to-
severe Crohn  ’  s disease (CD), the sponsor has conducted several 
large, randomized, controlled phase 3 clinical trials of infl  iximab 
maintenance therapy in IBD (hereaft  er referred to as   “  pivotal 
phase 3 trials  ”  ), including the ACCENT I (  5,6  ), ACCENT II (  7  ), 
and SONIC (  8  ) trials in CD and the ACT 1 and ACT 2 trials (  9  ) 
that formed the basis for approval of infl  iximab in ulcerative 
colitis (UC). 
  Although safety fi  ndings related to each of these studies have 
been reported in separate publications, a pooled analysis of key 
safety outcomes has been recently conducted for all sponsor-ini-
tiated infl  iximab trials in IBD, with emphasis on the fi  ve pivotal 
phase 3 trials that contribute nearly 90  %   of the data for patients 
in the pooled IBD safety analyses. Given the continued need for 
safety data related to TNF antagonism, fi  ndings of these analyses 
are detailed herein.     
  METHODS 
 Th   e 10 (7 CD, 3 UC) clinical trials included in these pooled analy-
ses represent the totality of the sponsor ’ s clinical safety database for 
infl  iximab in the treatment of adult patients with IBD. Th  e  pooled 
studies comprise fi  ve smaller trials (4 CD, 1 UC) evaluating a total 
of 244 patients (  10  –  15  ), 22 of whom contributed data to more 
than one treatment group per study, and fi  ve pivotal phase 3 trials 
evaluating infl  iximab maintenance therapy in 1,644 patients with 
CD (  5  –  8  ) and 741 patients with UC (  9  ), 184 of whom contributed 
data to more than one treatment group per study (  Tables 1  –  5 ). 
 Th  e fi  ve pivotal phase 3 trials, i.e., ACCENT I, ACCENT II, 
SONIC, ACT 1, and ACT 2, contributed approximately 89  %   
(2,119  /  2,385) of all patients with data in the overall pooled anal-
yses and were generally consistent in terms of study designs, in 
that they were all randomized, multicenter, double-blind trials that 
included a control group (  Table 1  ). Note that for four of the fi  ve 
pivotal phase 3 trials (ACCENT I, ACCENT II, ACT 1, and ACT 2), 
treatment with the immunomodulators AZA, 6-MP, and MTX or 
with corticosteroids was allowed during study participation, but 
such use was not a randomized study treatment. Each of these 
study protocols stipulated that patients would continue a stable 
regimen of baseline immunomodulator therapy throughout study 
participation. Conversely, the SONIC trial enrolled exclusively 
immunomodulator-na  ï  ve patients, and these patients were rand-
omized to receive AZA, 5     mg  /  kg of infl   iximab,  or  AZA  plus  5   mg /
  kg of infl  iximab (  8  ). 
  All study protocols were approved by the institutional review 
board at each participating site, and all patients provided written 
informed consent before beginning study participation. Janssen 
Biotech, Inc. (Horsham, PA) provided infl  iximab, active compa-
rator (AZA in the SONIC trial), and placebo (as appropriate) for 
intravenous infusion. 
  To evaluate the occurrence of uncommon events, safety data 
from the seven studies in CD (with the majority of the data 
coming from the pivotal ACCENT I, ACCENT II, and SONIC 
studies) were pooled and are reported as   ‘  CD studies  ’  . When 
pooled with data from the three   ‘  UC studies  ’   (with the majority of 
the data deriving from the pivotal ACT 1 and ACT 2 studies), they 
are reported as   ‘  IBD studies  ’  . Safety data from the pivotal phase 3 
trials in IBD, i.e., ACCENT I, ACCENT II, SONIC, ACT 1, 
and ACT 2, were also separately pooled across the three CD, 
two UC, and all fi  ve pivotal phase 3 IBD studies. Summaries of key 
design features of these studies are provided in   Table 1 . 
 Th   e incidences of adverse events per 100 patient-years (pt-yrs) 
of follow-up were calculated for infections, malignancies (includ-
ing both solid tumors and hematological malignancies and 
excluding nonmelanoma skin cancers) and deaths by treatment 
group (infl  iximab vs. placebo) and also by immunomodulator use 
(treatment vs. no treatment) for infections and malignancies as 
the quotient of the total number of events and pt-yrs of follow-up 
multiplied by 100; exact 95  %   confi  dence intervals (CIs) were also 
calculated. 
  For malignancies (excluding nonmelanoma skin cancer), 
standardized incidence ratios (SIRs) were also calculated as the 
quotient of the observed and expected numbers of patients with 
malignancy; 95  %   CIs were determined using exact methodol-
ogy. Th  e expected numbers of malignancy were derived using 
data adjusted for age, sex, and race from the general US popula-
tion in the Surveillance, Epidemiology, and End Results (SEER) 
database (  16  ). 
 Fisher ’ s exact test was used to compare the proportions of patients 
who experienced an adverse event of interest (e.g., infection, 
malignancy, or death) between treatment groups. Because a large 
number of safety parameters were evaluated, the Fisher  ’  s exact test 
is employed not for hypothesis testing but rather as an aid in signal 
detection to highlight diff  erences requiring closer examination. 
  All patients in ACCENT I and ACCENT II received infl  iximab 
5   mg / kg at week 0 and were therefore counted in the infl  iximab col-
umn in the calculation of pt-yrs of follow-up. Pt-yrs of follow-up 
for placebo were determined for the 161 placebo plus AZA-treated 
CD patients in the SONIC study plus additional placebo-treated 
patients from other CD studies (T08, T11, T16, and T20; see 
  Table 1  ) as applicable to the subpopulation being assessed. Note 
that infl  iximab use, both in combination with immunomodulators 
and alone, and immunomodulator use, both in combination with 
infl  iximab and alone, are pooled in these analyses such that infl  ixi-
mab use refers to any use of infl  iximab and immunomodulator use 
refers to any use of immunomodulators. Also note that the placebo 
group includes only patients who never received infl  iximab. 
  As noted above, infl  iximab treatment was generally randomized 
and blinded, while immunomodulator treatment, with the excep-
tion of the SONIC trial, refl  ects immunomodulator use at base-
line, i.e., immunomodulator use was not randomized or blinded 
and assumes that such use continued during the study. Protocols 
for these four of fi  ve pivotal phase 3 trials mandated that patients 
receiving a stable immunomodulator regimen at baseline would 
continue such use throughout study participation.     © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Pooled Safety Analyses of Infliximab in IBD 
            Table 1  .       Key features of 10 sponsor-initiated studies of inﬂ  iximab in IBD     
        Study (reference)       Pt. population        Study design   
    Treatment regimens 
(no. of pts. evaluated)   
    AE reporting 
period (wks)   
        Smaller trials of inﬂ  iximab in IBD                
           C0168T08 (  15  )   Severe CD (CDAI       >      150) 
refractory to corticosteroid 
therapy 
  Phase 1, SC, OL, single dose    Grp 1: Inﬂ  iximab 10    mg  /  kg (  n  =8) 
  Grp 2: Inﬂ  iximab 20    mg  /  kg (  n  =2) 
  8 
           C0168T11 (  10  )   Moderate-to-severe    a     CD    Phase 2, MC, OL, single dose, 
sequential dose-escalating trial 
  Grp 1: Inﬂ  iximab 1    mg  /  kg (  n  =5)   12 
               Grp 2: Inﬂ  iximab 5    mg  /  kg (  n  =5)    
               Grp 3: Inﬂ  iximab 10    mg  /  kg (  n  =5)    
               Grp 4: Inﬂ  iximab 20    mg  /  kg (  n  =6)    
           C0168T16 (  10,12,14  )   Moderate-to-severe    a     CD    Phase 2  /  3, MC, DB, PC, with 
initial dose-ranging treatment 
phase followed by repeated-
treatment phase plus OL treat-
ment for safety assessments 
    Initial dose-ranging phase 
(single dose)   
  Grp 1: Placebo (  n  =25) 
  Grp 2: Inﬂ  iximab 5    mg  /  kg (  n  =27) 
  Grp 3: Inﬂ  iximab 10    mg  /  kg (  n  =28) 
  Grp 4: Inﬂ  iximab 20    mg  /  kg (  n  =28) 
  16 (  n  =35) and 
48 (  n  =73) 
                 Open-label phase  : Inﬂ  iximab 10    mg  /  kg 
(  n  =48) 
   
                 Repeated-treatment phase   
(4    DB infusions) 
  Grp 1: Inﬂ  iximab 10    mg  /  kg q8wks 
(  n  =37) 
  Grp 2: Placebo q8wks (  n  =36) 
   
           C0168T20 (  11  )   Fistulizing CD    MC, DB, PC, randomized 
phase 3 trial 
  Grp 1: Inﬂ  iximab 10    mg  /  kg at wks 0, 2, 
6 (  n  =32) 
  52 
               Grp 2: Inﬂ  iximab 5    mg  /  kg at wks 0, 2, 
6 (  n  =31) 
   
               Grp 3: Placebo at wks 0, 2, 6 (  n  =31)    
           C0168T12 (  13  )   Active UC (modiﬁ  ed Truelove 
and Witts score       >      10) 
  MC, DB, PC, randomized 
phase 2 trial 
    Single dose of  : 
  Grp 1: Placebo (  n  =3) 
  Grp 2: Inﬂ  iximab 5    mg  /  kg (  n  =3) 
  Grp 3: Inﬂ  iximab 10    mg  /  kg (  n  =3) 
  Grp 4: Inﬂ  iximab 20    mg  /  kg (  n  =2) 
  12 
        Pivotal phase 3 trials of inﬂ  iximab in IBD                
           ACCENT I (  5,6  )   Moderate-to-severe    a     CD    MC, DB, PC, phase 3 
randomized trial 
  AZA, 6-MP, MTX, corticosteroids 
allowed but not randomized 
treatments 
  All pts.: Inﬂ  iximab 5    mg  /  kg at wk 0 
(  n  =573) 
  Grp 1: Placebo at wks 2, 6, and q8wks 
through wk 46 (  n  =188) 
  Grp 2: Inﬂ  iximab 5 mg  /  kg at wks 2, 6, 
and q8wks through wk 46 (  n  =192) 
  Grp 3: Inﬂ  iximab 5    mg  /  kg at wks 2 and 
6, then 10    mg  /  kg q8wks through wk 46 
(  n  =193) 
  54 
           ACCENT II (  7  )   Fistulizing CD    MC, DB, PC, phase 3 
randomized trial 
  All pts.: Inﬂ  iximab 5    mg  /  kg at wks 0, 2, 
6 (  n  =306) 
  54 
            AZA, 6-MP, MTX, corticosteroids 
allowed but not randomized 
treatments 
  Grp 1: Placebo at wk 14 and 
q8wks through wk 46 (crossover 
to 5    mg  /  kg possible;   n  =143 for 
placebo maintenance) 
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  RESULTS   
  Analysis groups and extent of exposure 
  Across the 10 sponsor-initiated infl   iximab trials in IBD (fi  ve 
smaller studies and fi  ve pivotal phase 3 studies conducted fol-
lowing infl  iximab  ’  s initial approval), safety data for 2,385 patients 
were available for pooled safety analyses (see   Tables 3  –  5 ).  Note 
that some patients presented in   Tables 1 and 2   contributed data 
to more than one treatment group in the analyses presented in 
  Tables  3 – 5  , e.g., 22 of the 244 patients in the fi  ve smaller studies 
and 33 of the 2,086 patients in the fi  ve pivotal trials. Data from 
the fi  ve pivotal trials were pooled for additional analyses, both 
across all fi  ve studies (  n     =    2,119)  and  across  the  three  CD  studies 
(  n     =    1,389)  or  2  UC  ( n     =    730)  studies  due  to  similarities  in  study 
design and homogeneity of the patient populations. In the 5 
pivotal IBD trials, 406 and 1,713 patients were treated with pla-
cebo and infl  iximab, respectively (  Table 3  ). Among the 2,117 
patients with documentation of immunomodulator use at base-
line (yes  /  no), 947 patients did and 1,170 patients did not receive 
the immunomodulators AZA, 6-MP, or MTX (  Tables 3 and 5 ). 
 Th  e extent of exposure to individual study agents for each 
of the pivotal phase 3 trials is summarized in   Table 2 ,  which 
includes infl  iximab infusions received during the main studies, 
as well as the blinded study extensions of SONIC and ACT 2. 
Excluding patients who initially received infl   iximab but who 
were later randomized to placebo maintenance treatment, CD 
patients received an average of 6.1  –  7.5 infl  iximab infusions and 
UC patients received an average of 6.3  –  6.5 infl  iximab infusions. 
Note that study agent administration in the SONIC and ACT 2 
main studies ended with the week-22 infusion and that safety 
data from week 30 through week 54 were collected as part of a 
blinded study extension, during which patients continued to 
receive blinded study agent.     
            Table 1  .       Continued     
        Study (reference)       Pt. population        Study design   
    Treatment regimens 
(no. of pts. evaluated)   
    AE reporting 
period (wks)   
               Grp 2: Inﬂ  iximab 5 mg  /  kg at wk 14 and 
q8wks through wk 46 (crossover to 
10    mg  /  kg possible;   n  =139 for inﬂ  iximab 
maintenance) 
   
           SONIC (  8  )   Moderate-to-severe    b     CD    MC, DB, ACC, phase 3 
randomized trial 
  Grp 1: AZA 2.5    mg  /  kg capsules  /  placebo 
infusions (  n  =161) 
  54    c     
            Na  ï  ve to IMs and biologics; 
patients randomized to 
IM treatment 
  Grp 2: Placebo capsules  /  inﬂ  iximab 
5    mg  /  kg infusions (  n  =163) 
  Grp 3: AZA 2.5    mg  /  kg capsules  /
  inﬂ  iximab 5    mg  /  kg infusions (  n  =179) 
  Capsules (daily)  /  infusions (wks 0, 2, 6, 
q8wks through wk 22) 
   
           ACT 1 (  9  )   UC (364) in pts. with Mayo 
score of 6  –  12 pts., Mayo 
endoscopic subscore of   ≥  2, and 
an inadequate response to or 
tolerance of oral corticosteroids, 
6-MP, and  /  or AZA 
  MC, DB, PC, phase 3 
randomized trial 
  AZA, 6-MP, corticosteroids 
allowed but not randomized 
treatments 
  Grp 1: Placebo at wks 0, 2, 6, and 
q8wks through wk 46 (  n  =121) 
  Grp 2: Inﬂ  iximab 5 mg  /  kg at wks 0, 
2, 6, and q8wks through wk 46 
(  n  =121) 
  Grp 3: Inﬂ  iximab 10 mg  /  kg at 
wks 0, 2, 6, and q8wks through 
wk 46 (  n  =122) 
  54 
           ACT 2 (  9  )   UC (364) in pts. with Mayo 
score of 6  –  12 pts., Mayo endo-
scopic subscore of   ≥  2, and an 
inadequate response to or toler-
ance of 5-ASAs, oral corticoster-
oids, 6-MP, and  /  or AZA 
  MC, DB, PC, phase 3 
randomized trial 
  AZA, 6-MP, corticosteroids 
allowed but not randomized 
treatments 
  Grp 1: Placebo at wks 0, 2, 6, and 
q8wks through wk 22 (  n  =123) 
  Grp 2: Inﬂ  iximab 5    mg  /  kg at 
wks 0, 2, 6, and q8wks through 
wk 22 (  n  =121) 
  Grp 3: Inﬂ  iximab 10    mg  /  kg at 
wks 0, 2, 6, and q8wks through 
wk 22 (  n  =120) 
  54    c     
          ACC, active-comparator-controlled; AE, adverse event; 5-ASAs, 5-aminosalicylates; AZA, azathioprine; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; 
DB, double-blind; IBD, inﬂ  ammatory bowel disease; IM, immunomodulators; MC, multicenter; 6-MP, 6-mercaptopurine; MTX, methotrexate; OL, open label;  PC, placebo-
controlled; pts., patients; q8wks, every 8 weeks; SC, single center; UC, ulcerative colitis; wks, weeks.     
      a        Baseline CDAI score between 220 and 400, inclusive.     
      b        Baseline CDAI score between 220 and 450, inclusive.     
      c        Dosing in the SONIC and ACT 2 main studies ended with the week-22 infusion. Safety data from week 30 through week 54 were collected as part of study extensions.     © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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system disorders (0.94 and 0.97  /  100 pt-yrs). Within these three 
system  –  organ classes, the most common serious infections were 
abscess (1.57 and 1.89 / 100 pt-yrs in placebo- and infl  iximab-treated 
IBD patients, respectively), gastro  enteritis (0.63 and 0.26  /  100 
pt-yrs), and pneumonia (0.31 and 0.66  /  100 pt-yrs) (  Table 3 ).   
  Malignancy 
  Across the 10 IBD trials and excluding nonmelanoma skin 
cancers, 13 patients (two placebo-treated, 11 infl  iximab-treated) 
had a malignancy during study participation. Of the malignancies, 
11 were non-lymphoma, while two patients had lymphoma. Both 
patients with lymphoma were infl  iximab-treated CD patients. One 
patient who received infl   iximab  5   mg / kg  at  week  0  followed  by 
placebo maintenance and AZA had natural killer cell lymphoma 
diagnosed aft  er study participation ended. A second patient with a 
history of AZA use received a single infusion of infl  iximab 10     mg  /
  kg and was diagnosed with intravascular B-cell lymphoma 9.5 
months aft  er the single infl  iximab infusion. Th  e non-lymphoma 
malignancies included breast (  n     =    2),  colon  ( n     =    2),  prostate  ( n     =     2 ) ,  
bladder (  n     =    1),  lung  ( n     =    1),  renal  ( n     =    1),  skin  ( n     =    1),  and  rectal 
(  n     =    1)  cancers  (9  infl  iximab-treated, 2 placebo). 
  When expressed on the basis of incidence (95  %   CI) per 100 
pt-yrs of follow-up, overlapping 95  %   CIs indicated that the 
incidences of malignancies were similar in the placebo- and 
infl  iximab-treated patients with CD (1.61 (0.19, 5.82) vs. 0.49 
(0.18, 1.06), respectively) and with UC (0.00 (0.00, 1.43) vs. 
0.60 (0.20, 1.40), respectively). Findings observed within the 
lymphoma and non-lymphoma malignancy subcategories were 
similar (  Table 4 ). 
 Th   e incidences of malignancies during only the controlled por-
tions of the 10 IBD trials were also determined. Four patients, two 
placebo-treated and two infl   iximab-treated, had a malignancy 
during the controlled study phases. No cases of lymphoma were 
documented during the controlled portions of the 10 IBD studies. 
  Infections 
 Th  e incidences of infections and serious infections were deter-
mined across the fi  ve pivotal phase 3 IBD trials. A larger propor-
tion of infl  iximab- than placebo-treated UC patients (50.1  %   vs. 
36.3 % ;   P         <       0.001) had at least one infection. Among CD patients, 
however, the proportions of patients who experienced at least 
one infection were similar between the infl  iximab- and placebo-
treated patients (49.1  %   vs. 45.3  %  ;   P     =    0.402).  Th  e proportions 
of patients who experienced at least one serious infection were 
also similar between placebo- and infl  iximab-treated  patients 
(  Table 3  ). When expressed on the basis of length of patient fol-
low-up, the incidences (95 %  CIs) per 100 pt-yrs of infections were 
132.81 (112.00, 156.36) in placebo- vs. 119.98 (113.67, 126.56) in 
infl  iximab-treated CD patients; 106.98 (93.43, 121.94) in placebo- 
vs. 105.41 (98.54, 112.63) in infl  iximab-treated UC patients; and 
115.79 (104.26, 128.25) in placebo- vs. 113.80 (109.12, 118.62) in 
infl  iximab-treated IBD patients. Similar patterns of overlapping 
95  %   CIs between the placebo and infl  iximab groups were also 
observed for serious infections (  Table 3 ). 
  When assessed by the patient  ’  s baseline immunomodula-
tor treatment (yes  /  no), the 95  %   CIs surrounding the incidences 
of infections and serious infections overlapped between patients 
treated with immunomodulators and those not treated with immu-
nomodulators in all patient populations (CD, UC, all IBD), with 
one exception. In patients with UC, but not CD, immunomodula-
tor treatment (vs. no treatment) yielded a higher incidence (95  %   
CI) of infections (120.07 (110.66, 130.08)  /  100 pt-yrs vs. 92.47 
(84.54, 100.94)  /  100 pt-yrs) (  Table 3 ). 
 A summary of the incidences of serious infections (per 100 pt-yrs 
of follow-up) by system  –  organ class and preferred term is also pro-
vided in   Table 3 .  Th   e most common serious infections were those 
considered resistance mechanism disorders (3.15 and 3.32  /  100 pt-
yrs in placebo- and infl  iximab-treated IBD patients, respectively), 
gastrointestinal disorders (0.63 and 1.07 / 100 pt-yrs), and respiratory 
    Table 2  .       Extent of exposure to inﬂ  iximab in the pivotal phase 3 IBD trials through week 46     
           Crohn’s disease       Ulcerative colitis   
            ACCENT I       ACCENT II       SONIC       ACT 1       ACT 2   
           PBO      a     
    INF 
5    mg  /  kg   
    INF 
10    mg  /  kg       PBO      b     
    INF 
5    mg  /  kg   
    AZA      +       
PBO   
    INF 
5    mg  /  kg      +       
PBO      c     
    INF 
5    mg  /  kg      +     
  AZA      c         PBO   
    INF 
5    mg  /  kg   
    INF 
10    mg  /  kg       PBO      c     
    INF 
5    mg  /  kg      c     
    INF 
10    mg  /  kg      c     
      Pts. 
treated 
  188   192   193   143   139   161   163   179   121   121   122   123   121   120 
      Average 
no. of 
inﬂ  iximab 
infusions 
  2.2   6.7   6.8   4.3   7.5   0.0   6.1   6.1   0.0   6.5   6.3   0.0   6.4   6.4 
          AZA, azathioprine; IBD, inﬂ  ammatory bowel disease; INF, inﬂ  iximab; pts., patients; PBO, placebo infusions, except for the INF      +      PBO group in SONIC, in which case: 
PBO, placebo capsules.     
      a        In ACCENT 1, placebo patients received 5    mg  /  kg inﬂ  iximab at week 0, and some of them also received episodic infusions of inﬂ  iximab 5    mg  /  kg.     
      b        In ACCENT II, placebo patients received 5    mg  /  kg inﬂ  iximab at weeks 0, 2, and 6 before randomization at week 14, and some of them also crossed over to receive 
infusions of inﬂ  iximab 5    mg  /  kg.     
      c        Including inﬂ  iximab infusions received during the main study and the blinded study extension.     The American Journal of GASTROENTEROLOGY  VOLUME 107 | JULY 2012   www.amjgastro.com
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  Lichtenstein   et al.   
                    Table 3  .       Summary of infections and serious infections through week 54 of the pivotal phase 3 inﬂ  iximab IBD studies by treatment and 
immunomodulator use     
           Crohn’s disease      a         Ulcerative colitis      a         All inﬂ  ammatory bowel disease      a     
           Placebo      b         Inﬂ  iximab       Placebo      b         Inﬂ  iximab       Placebo      b         Inﬂ  iximab   
      Pts. treated    161   1,228   245   485   406   1,713 
      Total  /  median pt-yrs of 
follow-up 
  108  /  0.7   1,127  /  1.0   209  /  0.6   831  /  1.0   318  /  0.6   1,958  /  1.0 
      No. (  %  ) of pts. with infection    73 (45.3  %  )   603 (49.1  %  )   89 (36.3  %  )   243 (50.1  %  )   162 (39.9  %  )   846 (49.4  %  ) 
             P  -value    c       0.402             <      0.001             <      0.001     
           Total incidence    144   1,352   224   876   368   2,228 
           Incidence per 100 pt-yrs    132.81   119.98   106.98   105.41   115.79   113.8 
           95  %   CI    d       (112.00, 156.36)    (113.67, 126.56)    (93.43, 121.94)    (98.54, 112.63)    (104.26, 128.25)    (109.12, 118.62) 
      No. (  %  ) of pts. with serious 
infection 
  9 (5.6  %  )   55 (4.5  %  )   6 (2.4  %  )   26 (5.4  %  )   15 (3.7  %  )   81 (4.7  %  ) 
             P  -value   0.547       0.085       0.427     
           Total incidence    9   86   6   42   15   128 
           Incidence per 100 pt-yrs    8.3   7.63   2.87   5.05   4.72   6.54 
           95  %   CI    (3.80, 15.76)    (6.10, 9.43)    (1.05, 6.24)    (3.64, 6.83)    (2.64, 7.78)    (5.45, 7.77) 
        System  –  organ class  /  common preferred terms (        >        0.20  /  per 100 pt-yrs per group)   
             Resistance mechanism 
disorder 
  5.53   4.44   1.91   1.8   3.15   3.32 
                Abscess   2.77   3.02   0.96   0.36   1.57   1.89 
                Fever   0   0.27   0   0.24   0   0.26 
                Infection   0   0.18   0.48   0.84   0.31   0.46 
                Sepsis   0.92   0.27   0   0.12   0.31   0.2 
                Cellulitis   0   0.27   0   0   0   0.15 
                Herpes zoster    0   0.27   0   0   0   0.15 
                Bacterial infection    1.84   0.09   0.48   0   0.94   0.05 
             Gastrointestinal system 
disorder 
  1.84   1.24   0   0.84   0.63   1.07 
                Gastroenteritis   1.84   0.18   0   0.36   0.63   0.26 
                Abdominal pain    0   0.27   0   0   0   0.15 
             Respiratory system disorder    0.92   0.44   0.96   1.68   0.94   0.97 
                Pneumonia   0.92   0.44   0   0.96   0.31   0.66 
                Sinusitis   0   0   0.48   0.12   0.31   0.05 
                  Upper respiratory 
infection 
  0   0   0.48   0   0.31   0 
             Skin and appendages 
disorder 
  0   0.53   0   0   0   0.31 
           Urinary system disorder    0   0.18   0   0.24   0   0.2 
             Body as a whole  –  general 
disorder 
  0   0.18   0   0   0   0.1 
           Cardiovascular disorder    0   0.18   0   0   0   0.1 
             Liver and biliary system 
disorder 
  0   0.09   0   0.12   0   0.1 
             Musculoskeletal system 
disorder 
  0   0.18   0   0   0   0.1 
           Reproductive disorder    0   0.09   0   0.12   0   0.1 © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Pooled Safety Analyses of Infliximab in IBD 
  Further, in all three of the patient populations (CD, UC, and 
all IBD), the 95  %   CIs surrounding the incidences of malignancy 
overlapped when compared between patients who were treated 
vs. those who were not treated with immunomodulators, with 
one exception. Among placebo-treated patients with CD, but 
not UC, those with immunomodulator use demonstrated a 
higher incidence (95  %   CI) of malignancy vs. no immunomodu-
lator treatment (1.84 (0.22, 6.66)  /  100 pt-yrs vs. 0.00 (0.00, 0.00)  / 
100 pt-yrs). 
  In a separate analysis comparing the observed incidences of 
malignancy with rates expected in the general US population based 
on the SEER database, all 95  %   CIs surrounding the malignancy 
SIRs contained 1 in all analysis groups (i.e., placebo and infl  iximab, 
with and without baseline immunomodulator use). Th  is  indicates 
that the incidences of malignancy observed in the controlled por-
tions of the pivotal phase 3 trials are not signifi  cantly diff  erent from 
the expected rates in the general US population. Similar fi  ndings 
were observed within the lymphoma and non-lymphoma malig-
nancy subcategories (  Table 4 ). 
When comparing the proportions of patients who had malignancy 
diagnosed during the studies (both overall and during the control-
led portions), results of Fisher  ’  s exact testing indicated no signifi  -
cant diff  erence between infl  iximab- and placebo-treated patients 
(  Table 4 ). 
  Further, when expressed as incidence (95  %   CI) per 100 pt-yrs 
of follow-up, the incidences of malignancy appeared similar in 
placebo- vs. infl  iximab-treated patients with CD (1.65 (0.20, 5.97) vs. 
0.00 (0.00, 1.00), respectively) and UC (0.00 (0.00, 2.18) vs. 0.60 (0.07, 
2.17), respectively). Consistent fi  ndings were observed within the 
lymphoma and non-lymphoma malignancy subcategories (  Table 4 ). 
 Th   e incidence of malignancy was also assessed by immunomod-
ulator use in the controlled portions of the fi  ve pivotal phase 3 
IBD trials. When comparing the proportions of patients who had 
malignancy diagnosed during the studies (both overall and during 
the controlled portions), results of Fisher  ’  s exact testing indicated 
no signifi  cant diff  erence between infl  iximab- and placebo-treated 
patients or between patients with and without immunomodulator 
use (  Table 4 ). 
                    Table 3  .       Continued     
           Nervous system disorder    0   0.09   0   0   0   0.05 
           Ear and hearing disorder    0   0   0   0.12   0   0.05 
             Myo-, endo-, pericardial, 
coronary and valve disorder 
  0   0   0   0.12   0   0.05 
           No immuno-
modulator      e     
    Immuno 
modulator      f     
    No immuno-
modulator      e     
    Immuno-
modulator      f     
    No immuno-
modulator      e     
    Immuno-
modulator      f     
      Pts. treated    776   613   394   334   1,170   947 
      Total  /  median pt-yrs of 
follow-up 
  715  /  1.0   520  /  1.0   541  /  0.8   500  /  1.0   1,256  /  1.0   1,020  /  1.0 
      Number (  %  ) of pts. with 
infection 
  397 (51.2  %  )   279 (45.5  %  )   169 (42.9  %  )   163 (48.8  %  )   566 (48.4  %  )   442 (46.7  %  ) 
             P  -value   0.04       0.117       0.457     
           Total incidence    918   578   500   600   1,418   1,178 
           Incidence per 100 pt-yrs    128.42   111.07   92.47   120.07   112.93   115.48 
           95  %   CI    (120.24, 137.00)    (102.20, 120.51)    (84.54, 100.94)    (110.66, 130.08)    (107.13, 118.97)    (108.98, 122.27) 
      Number (  %  ) of pts. with 
serious infections 
  36 (4.6  %  )   28 (4.6  %  )   14 (3.6  %  )   18 (5.4  %  )   50 (4.3  %  )   46 (4.9  %  ) 
             P  -value   1       0.277       0.53     
           Total incidence    63   32   18   30   81   62 
           Incidence per 100 pt-yrs    8.81   6.15   3.33   6   6.45   6.08 
           95  %   CI    (6.77, 11.28)    (4.21, 8.68)    (1.97, 5.26)    (4.05, 8.57)    (5.12, 8.02)    (4.66, 7.79) 
          AZA, azathioprine; CI, conﬁ  dence interval; IBD, inﬂ  ammatory bowel disease; 6-MP, 6-mercaptopurine; MTX, methotrexate; pts., patients; pt-yrs, patient-years.     
      a        Includes 3 Crohn’s disease and 2 ulcerative colitis, and thus a total of 5, pivotal phase 3 IBD studies.     
      b        With or without concomitant conventional therapy.     
      c          P  -values comparing treatment or immunomodulator use subgroups were calculated with the use of Fisher  ’  s exact test.     
      d        95  %   CIs based on an exact method.     
      e        No receipt of AZA, 6-MP, or MTX at baseline.     
      f        Receipt of AZA, 6-MP, or MTX at baseline.     The American Journal of GASTROENTEROLOGY  VOLUME 107 | JULY 2012   www.amjgastro.com
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  Lichtenstein   et al.   
            Table 4  .       Summary of malignancies (excluding nonmelanoma skin cancers) by treatment both overall and during the main portions of all 
inﬂ  iximab IBD studies    a     and by immunomodulator use during the controlled portions of the pivotal phase 3 IBD trials    b         
           Crohn’s disease       Ulcerative colitis       All inﬂ  ammatory bowel disease   
           Placebo      c         Inﬂ  iximab       Placebo      c         Inﬂ  iximab       Placebo      c         Inﬂ  iximab   
        Overall among all inﬂ  iximab IBD studies      a     
           Pts. treated    217   1,427   248   493   465   1,920 
                Total  /  median pt-yrs of follow-up    124  /  0.5   1,229  /  1.0   210  /  0.6   832  /  1.0   334  /  0.6   2,061  /  1.0 
           All malignancies 
                No. (  %  ) of pts. with malignancy    2 (0.9  %  )   6 (0.4  %  )   0 (0.0  %  )   5 (1.0  %  )   2 (0.4  %  )   11 (0.6  %  ) 
                  P  -value    d       0.286       0.175       1     
                Incidence per 100 pt-yrs    1.61   0.49   0   0.6   0.6   0.53 
                95  %   CI    e       (0.19, 5.82)    (0.18, 1.06)    (0.00, 1.43)    (0.20, 1.40)    (0.07, 2.16)    (0.27, 0.95) 
           Lymphoma                   
                No. (  %  ) of pts. with malignancy    0 (0.0  %  )   2 (0.1  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  )   2 (0.1  %  ) 
                  P  -value   1       0       1     
                Incidence per 100 pt-yrs    0   0.16   0   0   0   0.1 
                95  %   CI    (0.00, 2.41)    (0.02, 0.59)    (0.00, 1.43)    (0.00, 0.36)    (0.00, 0.90)    (0.01, 0.35) 
           Non-lymphoma malignancies                    
                No. (  %  ) of pts. with malignancy    2 (0.9  %  )   4 (0.3  %  )   0 (0.0  %  )   5 (1.0  %  )   2 (0.4  %  )   9 (0.5  %  ) 
                  P  -value   0.182       0.175       1     
                Incidence per 100 pt-yrs    1.61   0.33   0   0.6   0.6   0.44 
                95  %   CI    (0.19, 5.82)    (0.09, 0.83)    (0.00, 1.43)    (0.20, 1.40)    (0.07, 2.16)    (0.20, 0.83) 
        Controlled portions of all inﬂ  iximab IBD studies      a     
           Pts. treated    217   488   245   483   462   971 
                Total  /  median pt-yrs of follow-up    121  /  0.5   298  /  0.6   137  /  0.6   333  /  0.6   258  /  0.6   631  /  0.6 
           All malignancies                    
                No. (  %  ) of pts. with malignancy    2 (0.9  %  )   0 (0.0  %  )   0 (0.0  %  )   2 (0.4  %  )   2 (0.4  %  )   2 (0.2  %  ) 
                  P  -value   0.094       0.553       0.598     
                Incidence per 100 pt-yrs    1.65   0   0   0.6   0.77   0.32 
                95  %   CI    (0.20, 5.97)    (0.00, 1.00)    (0.00, 2.18)    (0.07, 2.17)    (0.09, 2.80)    (0.04, 1.15) 
           Lymphoma                   
                No. (  %  ) of pts. with malignancy    0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  ) 
                Incidence per 100 pt-yrs    0   0   0   0   0   0 
                95  %   CI    (0.00, 2.48)    (0.00, 1.00)    (0.00, 2.18)    (0.00, 0.90)    (0.00, 1.16)    (0.00, 0.47) 
           Non-lymphoma malignancies                    
                No. (  %  ) of pts. with malignancy    2 (0.9  %  )   0 (0.0  %  )   0 (0.0  %  )   2 (0.4  %  )   2 (0.4  %  )   2 (0.2  %  ) 
                  P  -value   0.094       0.553       0.598     
                Incidence per 100 pt-yrs    1.65   0   0   0.6   0.77   0.32 
                95  %   CI    (0.20, 5.97)    (0.00, 1.00)    (0.00, 2.18)    (0.07, 2.17)    (0.09, 2.80)    (0.04, 1.15) 
           No immuno-
modulator      f     
    Immuno 
modulator      g     
    No immuno-
modulator      f     
    Immuno 
modulator      g     
    No immuno-
modulator      f     
    Immuno-
modulator      g     
        Controlled portions of 5 pivotal IBD studies      b     
           Pts. treated    166   337   394   334   560   671 
           All malignancies 
                Total  /  median pt-yrs of follow-up    129  /  1.0   250  /  0.9   250  /  0.6   220  /  0.6   378  /  0.6   470  /  0.7 
                No. (  %  ) of pts. with malignancy    0 (0.0  %  )   2 (0.6  %  )   1 (0.3  %  )   1 (0.3  %  )   1 (0.2  %  )   3 (0.5  %  ) 
                  P  -value   1       1       0.631     
                Incidence per 100 pt-yrs    0   0.8   0.4   0.45   0.26   0.64 
                95  %   CI    (0.00, 2.33)    (0.10, 2.89)    (0.01, 2.23)    (0.01, 2.53)    (0.01, 1.47)    (0.13, 1.87) 
                Expected no. of pts.    h       0.43   0.71   1.22   0.88   1.65   1.6 
                SIR    i       0   2.8   0.82   1.13   0.61   1.88 
                SIR 95  %   CI    (0.00, 6.92)    (0.34, 10.11)    (0.02, 4.58)    (0.03, 6.30)    (0.02, 3.38)    (0.39, 5.48) © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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            Table 4  .       Continued         
           Crohn’s disease       Ulcerative colitis       All inﬂ  ammatory bowel disease   
       
    No immuno-
modulator      f     
    Immuno 
modulator      g     
    No immuno-
modulator      f     
    Immuno 
modulator      g     
    No immuno-
modulator      f     
    Immuno-
modulator      g     
           Placebo                   
                Pts. treated    0   161   137   108   137   269 
                Total  /  median pt-yrs of follow-up    0  /  0.0   108  /  0.7   75  /  0.6   62  /  0.6   75  /  0.6   170  /  0.6 
                No. of pts. (  %  ) with malignancy    0 (0.0  %  )   2 (1.2  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0. 0  %  )   2 (0.7  %  ) 
                  P  -value   0       0       0.552     
                Incidence per 100 pt-yrs    0   1.84   0   0   0   1.17 
                95  %   CI    (0.00, 0.00)    (0.22, 6.66)    (0.00, 3.97)    (0.00, 4.85)    (0.00, 3.97)    (0.14, 4.24) 
                Expected no. of pts.    0   0.35   0.35   0.23   0.36   0.59 
                SIR   0   5.7   0   0   0   3.41 
                SIR 95  %   CI    (0.00, 0.00)    (0.69, 20.59)    (0.00, 8.59)    (0.00, 12.76)    (0.00, 8.24)    (0.41, 12.33) 
           Inﬂ  iximab                    
                Pts. treated    166   176   257   226   423   402 
                Total  /  median pt-yrs of follow-up    129  /  1.0   142  /  1.0   174  /  0.6   158  /  0.6   303  /  0.6   300  /  0.7 
                No. of pts. (  %  ) with malignancy    0 (0.0  %  )   0 (0.0  %  )   1 (0.4  %  )   1 (0.4  %  )   1 (0.2  %  )   1 (0.3  %  ) 
                    P  -value (inﬂ  iximab vs. placebo)    0   0.228   1   1   1   0.568 
                    P  -value (no immunomodulator 
vs. immunomodulator) 
      0   1       1     
                Incidence per 100 pt-yrs    0   0   0.57   0.63   0.33   0.33 
                95  %   CI    (0.00, 2.33)    (0.00, 2.12)    (0.01, 3.20)    (0.02, 3.52)    (0.01, 1.84)    (0.01, 1.86) 
                Expected no. of pts.    0.43   0.36   0.82   0.65   1.29   1.01 
                SIR   0   0   1.22   1.54   0.78   0.99 
                SIR 95  %   CI    (0.00, 6.92)    (0.00, 8.24)      (0.03, 6.82)     (0.04, 8.57)    (0.02, 4.33)    (0.02, 5.50) 
           Lymphoma                   
                No. (  %  ) of pts. with malignancy    0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  )   0 (0.0  %  ) 
                Incidence per 100 pt-yrs    0   0   0   0   0   0 
                95  %   CI    (0.00, 2.33)    (0.00, 2.12)    (0.00, 1.72)    (0.00, 1.89)    (0.00, 0.99)    (0.00, 1.00) 
                Expected no. of pts.    0.02   0.02   0.04   0.03   0.05   0.05 
                SIR   0   0   0   0   0   0 
                SIR 95  %   CI    (0.00, 157.21)    (0.00,163.60)   (0.00, 83.69)    (0.00, 101.69)    (0.00, 54.61)    (0.00, 62.71) 
           Non-lymphoma malignancies                    
                No. (  %  ) of pts. with malignancy    0 (0.0  %  )   0 (0.0  %  )   1 (0.4  %  )   1 (0.4  %  )   1 (0.2  %  )   1 (0.3  %  ) 
                  P  -value   0       1       1     
                Incidence per 100 pt-yrs    0   0   0.57   0.63   0.33   0.33 
                95  %   CI    (0.00, 2.33)    (0.00, 2.12)    (0.01, 3.20)    (0.02, 3.52)    (0.01, 1.84)    (0.01, 1.86) 
                Expected no. of pts.    0.41   0.35   0.82   0.62   1.23   0.97 
                SIR   0   0   1.22   1.61   0.81   1.03 
                SIR 95  %   CI    (0.00, 7.24)    (0.00, 8.67)    (0.03, 6.82)    (0.04, 8.98)    (0.02, 4.53)    (0.03, 5.77) 
          AZA, azathioprine; CI, conﬁ  dence interval; IBD, inﬂ  ammatory bowel disease; 6-MP, 6-mercaptopurine; MTX, methotrexate; pts., patients; pt-yrs, patient-years; SEER, 
Surveillance, Epidemiology, and End Results; SIR, standardized incidence ratio.     
      a        Includes 7 Crohn’s disease and 3 ulcerative colitis, and thus a total of 10, IBD studies.     
      b        Includes 3 Crohn’s disease and 2 ulcerative colitis, and thus a total of 5 pivotal phase 3 IBD studies.     
      c        With or without concomitant conventional therapy.     
      d          P  -values comparing treatment or immunomodulator use subgroups were calculated with the use of Fisher’s exact test. Note that   P  -values cannot be computed when a 
group has no patients or when neither group has such an event.     
      e        95  %   CIs based on an exact method.     
      f        No receipt of AZA, 6-MP, or MTX at baseline.     
      g        Receipt of AZA, 6-MP, or MTX at baseline.     
      h        Based on the SEER database (2002) adjusted for age, sex, and race.     
      i        Calculated as the quotient of the observed and expected numbers of patients with malignancy.     The American Journal of GASTROENTEROLOGY  VOLUME 107 | JULY 2012   www.amjgastro.com
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  Lichtenstein   et al.   
  In addition to the malignancies discussed above, among 
the 2,385 patients with IBD included in these analyses (465 
placebo, 1,920 infl  iximab),  fi   ve patients (3 infl  iximab-treated, 
2 placebo-treated) had basal cell carcinoma and two patients 
(both infl  iximab-treated) had malignant skin neoplasm.     
  Mortality 
  Five patients died during the 10 IBD trials. Th   e deaths included 
a patient (63-year-old female with baseline immunomodula-
tor use) with CD in SONIC who received AZA monotherapy 
and died of sepsis following a colectomy; three infl  iximab-
treated patients with CD in ACCENT I who died of septic shock 
(35-year-old female with no baseline immunomodulator use), 
sepsis (57-year-old female with no baseline immunomodulator 
use), and myocardial infarction (37-year-old male with baseline 
immunomodulator use); and one infl  iximab-treated patient with 
UC in ACT 2 (56-year-old male with baseline immunomodulator 
use) who died following diagnosis of pulmonary histoplasmosis 
during the open-label, long-term, follow-up period. 
 Given the longer follow-up periods for infl  iximab-treated patients, 
when summarized as incidence (95 %  CI) per 100 pt-yrs of follow-up, 
overlapping CIs indicated no increase in mortality with infl  iximab 
vs. placebo treatment among patients with CD (0.24 (0.05, 0.71) vs. 
0.80 (0.02, 4.48), respectively), UC (0.12 (0.00, 0.67) vs. 0.00 (0.00, 
1.43), respectively), or IBD (0.19 (0.05, 0.50) vs. 0.30 (0.01, 1.67), 
respectively). Th   e same was true for infection-related deaths, which 
    Table 5  .       Summary of mortality through week 54 by treatment (all IBD studies) and immunomodulator use status (pivotal phase 3 IBD 
trials) 
           Crohn’s disease      a         Ulcerative colitis      a         All inﬂ  ammatory bowel disease      a     
           Placebo      b         Inﬂ  iximab       Placebo      b         Inﬂ  iximab       Placebo      b         Inﬂ  iximab   
      Pts. treated    217   1,427   248   493   465   1,920 
      Total  /  median pt-yrs of 
follow-up 
  124  /  0.5   1,230  /  1.0   210  /  0.6   833  /  1.0   334  /  0.6   2,063  /  1.0 
        Deaths   
           No. (  %  ) of pts.    1 (0.5  %  )   3 (0.2  %  )   0 (0.0  %  )   1 (0.2  %  )   1 (0.2  %  )   4 (0.2  %  ) 
             P  -value    c       0.433       1       1     
           Incidence  /  100 pt-yrs    0.8   0.24   0   0.12   0.3   0.19 
           95  %   CI    d       (0.02, 4.48)    (0.05, 0.71)    (0.00, 1.43)    (0.00, 0.67)    (0.01, 1.67)    (0.05, 0.50) 
        Infection-related deaths   
           No. (  %  ) of pts.    1 (0.5  %  )   2 (0.1  %  )   0 (0.0  %  )   1 (0.2  %  )   1 (0.2  %  )   3 (0.2  %  ) 
             P  -value   0.346       1       0.58     
           Incidence  /  100 pt-yrs    0.8   0.16   0   0.12   0.3   0.15 
           95  %   CI    (0.02, 4.48)    (0.02, 0.59)    (0.00, 1.43)    (0.00, 0.67)    (0.01, 1.67)    (0.03, 0.43) 
            No immuno-
modulator      e     
    Immuno-
modulator      f     
    No immuno-
modulator      e     
    Immuno-
modulator      f     
    No immuno-
modulator      e     
    Immuno-
modulator      f     
      Pts. treated    776   613   394   334   1,170   947 
      Total  /  median pt-yrs of 
follow-up 
  715  /  1.0   520  /  1.0   541  /  0.8   500  /  1.0   1,256  /  1.0   1,020  /  1.0 
        Deaths   
           No. (  %  ) of pts.    2 (0.3  %  )   2 (0.3  %  )   0 (0.0  %  )   1 (0.3  %  )   2 (0.2  %  )   3 (0.3  %  ) 
             P  -value   1       0.459       0.662     
           Incidence  /  100 pt-yrs    0.28   0.38   0   0.2   0.16   0.29 
           95  %   CI    (0.03, 1.01)    (0.05, 1.39)    (0.00, 0.55)    (0.01, 1.11)    (0.02, 0.58)    (0.06, 0.86) 
          AZA, azathioprine; CI, conﬁ  dence interval; IBD, inﬂ  ammatory bowel disease; 6-MP, 6-mercaptopurine; MTX, methotrexate; pts., patients; pt-yrs, patient-years.     
      a        Includes 7 Crohn’s disease and 3 ulcerative colitis, or a total of 10, IBD studies when summarized by treatment and 3 Crohn’s disease and 2 ulcerative colitis, or a total 
of 5, pivotal phase 3 IBD studies when summarized by baseline immunomodulator use.     
      b        With or without concomitant conventional therapy.     
      c          P  -values comparing treatment or immunomodulator use subgroups were calculated with the use of Fisher’s exact test.     
      d        95  %   CIs based on an exact method.     
      e        No receipt of AZA, 6-MP, or MTX at baseline.     
      f        Receipt of AZA, 6-MP, or MTX at baseline.     © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Pooled Safety Analyses of Infliximab in IBD 
to the relatively low incidence of serious infections, regardless of 
immunomodulator use, as such an eff  ect could off  set any small 
increase in serious infections that might be associated with the 
immunosuppressive nature of these drugs. Th  ese fi  ndings are 
also consistent with additional data from the TREAT Registry 
that indicated that the risk for serious infection in infl  iximab-
treated CD patients is similar to that for patients receiving con-
ventional immunomodulators (  21  ). Despite our observation of 
no increase in serious infections, all patients should be screened 
for pre-existing infections before the start of any immunosup-
pressive therapy. 
  Overall, 13 patients (2 placebo-treated, 11 infl  iximab-treated) 
had a malignancy (excluding nonmelanoma skin cancer) during 
the 10 IBD trials, equating to incidences of 0.60 and 0.53  /  100 pt-
yrs, among placebo- and infl  iximab-treated IBD patients, respec-
tively. Two of the malignancies in infl  iximab-treated CD patients 
were lymphomas; the 11 other malignancies across both cohorts 
were non-lymphoma. 
 During the controlled portions of the 10 IBD trials, four patients 
(2 placebo, 2 infl  iximab) had a malignancy, all non-lymphoma, 
equating to incidences of 0.77 and 0.32  /  100 pt-yrs, respectively, 
of placebo- and infl  iximab-treated IBD patients. Th  e incidence 
of malignancy was not higher with infl  iximab treatment, nor 
was it signifi  cantly impacted by immunomodulator use. In a sep-
arate analysis comparing the observed incidences of malignancy 
with rates expected in the general US population based on the 
SEER database, the incidence of malignancy was not signifi  cantly 
diff  erent. 
  A higher incidence of malignancy was observed in placebo-
treated patients receiving vs. those not receiving immunomodu-
lators. Th  ese fi   ndings may support others suggesting that the 
thiopurines AZA and 6-MP are associated with a moderately 
increased risk of malignancy, particularly lymphoproliferative dis-
ease. Specifi  cally, in a French cohort of nearly 20,000 patients with 
IBD (60  %   with CD, 40  %   with UC or unclassifi  ed IBD) followed 
for an average of 35 months, the risk of lymphoproliferative dis-
order was 5 times higher in patients exposed to thiopurines than 
in those never exposed to these drugs. Older age, male sex, and 
longer duration of IBD were also associated with increased risk 
of lymphoproliferative disorder in the French cohort (  22  ). Also, 
as noted above, results of a retrospective safety analysis of 799 
German IBD patients treated with thiopurines and  /  or TNF 
antagonists between 2002 and 2010 indicated an elevated risk of 
malignancy (4.2  %   vs. 1.5  %  ,   P     =    0.024,  odds  ratio    =    2.86)  in  patients 
treated with only thiopurines relative to patients treated with TNF 
antagonists with or without thiopurines (  20  ). 
  We also determined malignancy SIRs within the groups of 
patients with and without baseline immunomodulator use. 
Results of these pooled analyses indicated no signifi  cant diff  er-
ence from the expected rates in the general US population. Con-
versely, recently reported results of a meta-analysis of 26 studies 
of infl  iximab, adalimumab, and certolizumab, including almost 
9,000 CD patients, indicated that use of anti-TNF agents with 
immunomodulators is associated with an increased, albeit small 
(6.1  /  10,000 pt-yrs), risk of non-Hodgkin  ’  s lymphoma relative to 
accounted for four of the fi  ve deaths. Overlapping 95 %  CIs were also 
observed in a separate analysis of mortality by immunomodulator 
use in the fi  ve pivotal phase 3 IBD trials (  Table 5 ).    
  DISCUSSION 
  Since receiving marketing authorization for the treatment of 
CD more than a decade ago, infl  iximab has gained wide accept-
ance as a highly eff  ective treatment option for IBD. As a result, 
longer-term safety data are becoming available. No diff  erence 
in the incidence of neoplasia between adult patients with CD 
who were (  n     =    404)  and  were  not  ( n     =    404)  treated  with  infl  ixi-
mab was reported by Biancone   et al   (  17  ). An additional 4 years 
of follow-up of 591 of the patients in this matched-pair study 
yielded consistent fi   ndings,  with  3.9 %   (12 / 304)  of  infl  iximab-
treated patients and 4.2  %   (12  /  287) of patients not treated with 
infl   iximab diagnosed with neoplasia (  P     =    0.95)  ( 18 ).  Fidder 
  et al.   (  19  ), who retrospectively examined medical records of 734 
infl  iximab-treated IBD patients and 666 controls, also observed 
no diff  erence between the two groups in mortality, malignancy 
including lymphoma, or infection rate. In a retrospective safety 
analysis of 799 German IBD patients treated with thiopurines 
and  /  or TNF antagonists between 2002 and 2010, an elevated 
risk of malignancy (4.2  %   vs. 1.5  %  ,   P     =    0.024,  odds  ratio    =    2.86), 
but not infection (14.4  %   vs. 15.5  %  ,   P     =    0.69),  was  observed  in 
patients treated with only thiopurines relative to patients treated 
with TNF antagonists with or without thiopurines (  20  ). Results 
of several large randomized phase 3 clinical trials of infl  iximab 
maintenance therapy in IBD, including the ACCENT I (  5,6  ), 
ACCENT II   (7),   and SONIC (  8  ) trials in CD and the ACT 1 and 
ACT 2 trials (  9  ) in UC also contribute to the growing body of 
infl  iximab safety data. 
  Findings presented herein from a pooled analysis of key safety 
outcomes, derived from 10 sponsor-conducted IBD studies with 
large cohorts of IBD patients treated by referral centers in daily 
practice, are generally consistent with conclusions drawn by 
Biancone   et al.   ( 17,18 )  and  Fidder   et al.   ( 19 ).  Specifi  cally, results 
of our pooled analyses of infl  iximab safety data in the treatment 
of IBD indicate no increase in infections or serious infections 
with infl  iximab vs. placebo treatment in patients with CD or UC. 
Independent of infl   iximab use, immunomodulator treatment 
did not appear to increase the incidence of infections or serious 
infections in patients with CD but did yield a higher incidence 
of infection vs. no immunomodulator treatment in patients with 
UC. One explanation for the lack of an increase in the incidence 
of serious infections with either infl  iximab or immunomodula-
tors in CD is that many of the complications of CD are inherently 
infectious in nature and may be decreased by eff  ective CD ther-
apy. Results derived from the TREAT Registry of CD patients, 
which included assessment of the role of corticosteroids in infec-
tious complications, have shown that infl  iximab allows for steroid 
tapering and discontinuation in CD (  21  ). Several of the protocols 
for the pivotal phase 3 trials included in this report mandated 
steroid tapering during the early phase of the trial. Th  e  lower  ster-
oid consumption in the reported CD trials may also contribute The American Journal of GASTROENTEROLOGY  VOLUME 107 | JULY 2012   www.amjgastro.com
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the expected rate of non-Hodgkin  ’  s lymphoma derived from the 
SEER  database,  i.e.,  1.9 / 10,000  pt-yrs  (SIR  (95 %   CI)    =    3.23  (1.5, 
6.9)), and also relative to the expected rate for CD patients treated 
with only immunomodulators, i.e., 4.0  /  10,000 pt-yrs (SIR (95  %   
CI)       =       1.70 (0.5, 7.1)) (  23  ). As noted above, no cases of lymphoma 
were reported during the controlled portions of the trials com-
prising our pooled analyses. In addition to the malignancies 
discussed above, among the 2,385 patients with IBD included 
in these analyses (465 placebo, 1,920 infl  iximab), fi  ve patients 
(3 infl  iximab-treated, 2 placebo-treated) had basal cell carcinoma 
and two patients (both infl  iximab-treated) had nonmelanoma 
malignant skin neoplasm. It is still not certain whether or not inf-
liximab use increases the risk of malignancy, but it is possible that 
the impact of infl  iximab is no worse than that of conventional 
immunomodulators and that, by eff  ectively controlling infl  am-
mation, infl  iximab may contribute to a lower malignancy risk 
in IBD. Th   e latter possibility requires further confi  rmation with 
longer-term data. 
  Consistent with published reports citing no evidence of 
increased mortality in CD patients treated with anti-TNF 
agents (  19,20,24  ), we observed no diff   erence in mortality 
between placebo- and infl  iximab-treated patients with either CD 
or UC. Th  e same was true for infection-related deaths, which 
accounted for four of the fi  ve deaths. Immunomodulator treat-
ment was also unassociated with increases in mortality in these 
IBD patients. 
  One point to note in the interpretation of these data is that, 
with the exception of the SONIC trial (  8  ), immunomodula-
tor treatment was not randomized, blinded, or controlled and 
refl  ects patient treatment at the time of study entry (as study pro-
tocols stipulated that any baseline immunomodulator treatment 
regimen would remain stable throughout study participation). 
It therefore remains possible that any higher event incidence 
in the immunomodulator-treated patients refl  ects their having 
more severe IBD rather than immunomodulator use itself. For 
this reason, any comparison between event rates between inf-
liximab vs. immunomodulators must be made with caution. Still, 
the data of Fidder   et al.   ( 19 )  showed  no  diff  erence in the rates 
of infection, malignancy including lymphoma, and mortality 
between IBD patients treated with infl  iximab and IBD patients 
treated with conventional therapies. It should also be noted, how-
ever, that the overall pooled results do not diff  er from those of 
the SONIC trial, in which both treatment with infl  iximab and 
treatment with immunomodulators were randomized in a con-
trolled trial. It is also important to note that the relatively short 
period of follow-up, along with the relative lack of power inher-
ent in these clinical trial data for determining treatment group 
diff  erences in rare safety events, limit our ability to draw defi  ni-
tive conclusions from these analyses. Th   e powering, however, is 
fairly good for detecting a doubling or tripling of the malignancy 
rate, both of which are clinically important to exclude. Th  e  2,061 
pt-yrs of follow-up from the infl  iximab-treated IBD cohort in 
this paper would yield 71  %   or 99  %   power to detect a doubling 
or tripling in malignancy incidence, respectively. Representing 
data derived from rigorous clinical trials, therefore, the current 
data are somewhat reassuring and have merit when assessing the 
overall safety of anti-TNF agents. 
  When taken together, results of these pooled analyses indicate 
no increase in serious infection, mortality, or malignancy, includ-
ing lymphoma in association with infl  iximab treatment of IBD. 
In addition, the safety of infl  iximab in these analyses appears 
comparable to that of conventional immunomodulators.           
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  Study  Highlights  
    WHAT IS CURRENT KNOWLEDGE   
   3  The anti-tumor necrosis factor (TNF) agent inﬂ  iximab has 
been used to treat patients with moderately-to-severely active 
inﬂ  ammatory bowel disease for more than a decade. 
   3  Safety issues unique to TNF inhibitors, including life-
threatening and opportunistic infection, malignancy, and 
mortality, continue to be monitored. 
    WHAT IS NEW HERE   
   3  We completed a pooled analysis of key safety outcomes for 
all Janssen-sponsored major clinical trials of inﬂ  iximab in 
inﬂ  ammatory bowel disease (IBD). 
   3  Pooled safety data indicate no increase in serious infection, 
mortality, or malignancy, including lymphoma, with inﬂ  iximab 
vs. conventional immunomodulators in the treatment of IBD. 
   3  The safety data on inﬂ  iximab in a large number of IBD 
patients is reassuring.                  
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